Free shipping on all orders over $ 500

AZD4573

Cat. No. M10706
AZD4573 Structure
Size Price Availability Quantity
5mg USD 300  USD300 In stock
10mg USD 470  USD470 In stock
25mg USD 800  USD800 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

AZD4573 is a potent and highly selective CDK9 inhibitor (IC50 values less than 4 nM) can be used to study hematologic malignancies.

Chemical Information
Molecular Weight 429.94
Formula C22H28ClN5O2
CAS Number 2057509-72-3
Solubility (25°C) DMSO ≥ 50 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Linzhang Li, et al. J Healthc Eng. Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis

[2] Bing Z Carter, et al. Haematologica. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition

[3] Bernard Barlaam, et al. J Med Chem. Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies

[4] Clara Alcon, et al. Clin Cancer Res. A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies

[5] Justin Cidado, et al. Clin Cancer Res. AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells

Related CDK Products
PF-07224826

PF-07224826 is a CDK2/4/6 inhibitor.

INCB123667

INCB123667 is a CDK2 inhibitor.

Senexin B

Senexin B is a potent, orally active CDK8/19 inhibitor with Kd values of 140 nM and 80 nM for CDK8 and CDK19, respectively.

Q901

Q901 is a CDK7 inhibitor for tumor-related studies.

NUV-422

NUV-422 is a CDK2/4/6 inhibitor that can be used in studies related to malignant gliomas.

  Catalog
Abmole Inhibitor Catalog




Keywords: AZD4573 supplier, CDK, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.